April 12, 2006 — Novacea, Inc. today announced the initiation of ASCENT-2, its pivotal Phase 3 clinical study evaluating the combination of the Company’s novel oral anti-cancer agent, DN-101, and TaxotereŽ (docetaxel) in men with prostate cancer for whom hormonal therapy is no longer working, also known as androgen-independent prostate cancer (AIPC). This randomized, controlled, multi-national [...]
Read The Full Article:
http://www.drilltools.org/282
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
Powered by blogdig.net